The role of osteoanabolic agents in the management of patients with osteoporosis
- PMID: 35635798
- DOI: 10.1080/00325481.2022.2069582
The role of osteoanabolic agents in the management of patients with osteoporosis
Abstract
Reducing fracture risk is the objective of osteoporosis treatment. Bone-forming osteoporosis drugs increase bone mass, restore bone microarchitecture, and reduce fracture risk more effectively than oral bisphosphonates, providing strong justification for the use of these agents as the initial therapy or after anti-remodeling agents in patients at very high risk of fracture. At the end of a 12-to-24-month course of osteoanabolic therapy, transitioning to a potent anti-remodeling agent maintains and enhances the treatment benefit. This review describes the clinical applications of osteoanabolic therapy for osteoporosis.
Keywords: Osteoporosis; abaloparatide; osteoanabolic; romosozumab; sequence; teriparatide.
Similar articles
-
Role of bone-forming agents in the management of osteoporosis.Aging Clin Exp Res. 2021 Apr;33(4):775-791. doi: 10.1007/s40520-020-01708-8. Epub 2021 Feb 16. Aging Clin Exp Res. 2021. PMID: 33594648 Review.
-
Osteoanabolic therapy for osteoporosis in women.Climacteric. 2022 Feb;25(1):60-66. doi: 10.1080/13697137.2021.1953463. Epub 2021 Aug 3. Climacteric. 2022. PMID: 34342243 Review.
-
Osteoanabolic and dual action drugs.Br J Clin Pharmacol. 2019 Jun;85(6):1084-1094. doi: 10.1111/bcp.13766. Epub 2019 Apr 3. Br J Clin Pharmacol. 2019. PMID: 30218587 Free PMC article. Review.
-
New therapeutic targets for osteoporosis.Maturitas. 2019 Feb;120:1-6. doi: 10.1016/j.maturitas.2018.11.010. Epub 2018 Nov 16. Maturitas. 2019. PMID: 30583758 Review.
-
Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?Eur J Endocrinol. 2024 Jul 2;191(1):R9-R21. doi: 10.1093/ejendo/lvae076. Eur J Endocrinol. 2024. PMID: 38938063 Review.
Cited by
-
Recommendations for the optimal use of bone forming agents in osteoporosis.Aging Clin Exp Res. 2024 Aug 9;36(1):167. doi: 10.1007/s40520-024-02826-3. Aging Clin Exp Res. 2024. PMID: 39120740 Free PMC article. Review.
-
Real-world efficacy of a teriparatide biosimilar (RGB-10) compared with reference teriparatide on bone mineral density, trabecular bone score, and bone parameters assessed using quantitative ultrasound, 3D-SHAPER® and high-resolution peripheral computer tomography in postmenopausal women with osteoporosis and very high fracture risk.Osteoporos Int. 2024 Aug 2. doi: 10.1007/s00198-024-07208-z. Online ahead of print. Osteoporos Int. 2024. PMID: 39093439
-
A crossover comparison of patient satisfaction with two teriparatide regimens: primary results of the Japanese Osteoporosis Intervention Trial 06 (JOINT-06).J Bone Miner Metab. 2024 Sep;42(5):582-590. doi: 10.1007/s00774-024-01521-7. Epub 2024 Jun 11. J Bone Miner Metab. 2024. PMID: 38861178 Free PMC article. Clinical Trial.
-
Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials.Osteoporos Int. 2024 Jul;35(7):1195-1204. doi: 10.1007/s00198-024-07049-w. Epub 2024 Apr 4. Osteoporos Int. 2024. PMID: 38573517 Free PMC article. Clinical Trial.
-
[Teriparatide regulates osteoblast differentiation in high-glucose microenvironment through the cAMP/PKA/CREB signaling pathway].Nan Fang Yi Ke Da Xue Xue Bao. 2023 Jan 20;43(1):39-45. doi: 10.12122/j.issn.1673-4254.2023.01.05. Nan Fang Yi Ke Da Xue Xue Bao. 2023. PMID: 36856208 Free PMC article. Chinese.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical